Rifaximin Medicine 09 January 2018 Extended indication Prikkelbaredarmsyndroom. Therapeutic value No judgement Total cost € 999,600,000.00 Registration phase Unknown Product Active substance Rifaximin Domain Chronic immune diseases Reason of inclusion Main indication Bowel diseases Extended indication Prikkelbaredarmsyndroom. Current proprietary name Already available biosimilars / generics Proprietary name Xifaxan Manufacturer Norgine Portfolio holder Mechanism of action Unknown Route of administration Oral Therapeutical formulation Tablet Budgetting framework Extramural (GVS) Centre of expertise Additional remarks Antibioticum dat al beschikbaar is in Nederland. Registration Registration route Centralised (EMA) Type of trajectory Unknown Particularity Unknown ATMP Unknown Submission date Expected Registration Orphan drug No Registration phase Unknown Reimbursement Medicine sluice Additional remarks Therapeutic value Current treatment options Therapeutic value No judgement This assessment does not indicate any potential inclusion in the package. Substantiation Duration of treatment Frequency of administration 2 times a day Dosage per administration 550 mg References Additional remarks Expected patient volume per year Patient volume < 238,000 Market share is generally not included unless otherwise stated. Maximum patient volume for sluice References NHG Additional remarks De prevalentie is voor mannen 4 per 1000 en voor vrouwen 10 per 1000. (NHG). 17 mln*14/1000= 238.000 personen maximaal. Expected cost per patient per year Cost € < 4,200.00 This amount gives an indication of the total cost. It is the result of the average expected patient volume times the average cost per patient. both per year. References Medicijnkosten.nl Additional remarks €6,08 per pil van 550mg. € 4441,06 pppj Potential total cost per year Total cost € 999,600,000.00 Total cost for sluice Additional remarks Off label use Off label use Unknown Indications off label use References Additional remarks Indication extension Indication extensions Unknown Indication extensions References Additional remarks Other information Additional remarks